Even though several studies highlighted the role of maternal thyroid hormones (THs) TRs. In vivo,, was observed as early as E11. 5-E12.5 in different primordia (i.e. central nervous system, sense organs, intestine, etc.) 
T3 concentration in the intracellular and nuclear compartments is dependent on (i ) the circulating levels of THs, (ii ) their rates of entry and exit in and out of the cell and the nucleus, (iii ) the rate of T4 to T3 conversion and (iv) T3 degradation in the cell
. The formation and degradation of T3 in tissues are dependent primarily on the activities of three selenodeiodinases (type 1, type 2 and type 3) that catalyse the selective removal of iodine from iodothyronines and convert the precursor T4 into the active hormone T3, and the inactive hormones reverse T3 and T2 [3] . Importantly, the cellular uptake and the release of THs are mediated by transporters. Among these, monocarboxylate transporter 8 (MCT8) is particularly important in the transport of T3 into the brain [4, 5] .
THs are necessary for differentiation, growth and metabolism in mammals as well as lower organisms [6] . Its biological action is mediated by thyroid hormone receptors (TRs) binding to TH-responsive elements (TREs) in the regulatory regions of target genes that regulate gene transcription by chromatin remodelling [7, 8] . In the absence of TH, TRs bind a complex of inhibitory proteins that promote deacetylation and inhibit gene transcription [9] . Recently another mechanism by which the nuclear corepressor NCoR modulates expression of positive TRs targets and regulates the response to set levels of T3 was demonstrated [10] . [11, 12] . T4 has been found in human embryonic cavities in the first trimester of pregnancy, thus suggesting that maternal T4 could cross the placenta. From the coelomic fluid it may reach the embryo via the yolk sac, and may be functionally important for the developing embryo, while its own thyroid is not yet functioning [13] . In addition, significant levels of total T4 were found in umbilical cord sera of term neonates affected by congenital hypothyroidism, unable to produce any T4 due to total iodide organification defects. After birth, T4 serum levels gradually decreased, and became undetectable within 2 weeks, thus indicating that substantial amounts of T4 are transferred from mother to foetus during late gestation [14] . Nuclear T3 receptor has been interestingly found in human foetal brain, liver, heart and lung at early and mid gestation [15, 16] . [7, 17] . Both maternal hypothyroidism and hyperthyroidism have deleterious effects on the outcome of human pregnancy [18] . High maternal THs levels (not associated with autoimmune thyroid disease), by itself, produce foetal thyrotoxicosis, impair embryogenesis and cause higher miscarriage rates through a direct toxic effect of excess THs on the human foetus [18] . [7, [19] [20] [21] ; (ii ) inappropriate gene expression in foetal rat brain [22, 23] and (iii ) alterations in cell migration in the cerebral cortex and hippocampus [19, 24, 25] .
Both T4 and T3 have been importantly detected in the rat embryo and foetal brain before the onset of foetal thyroid function (FTF)

Indeed, maternal THs have been consistently described to play a crucial biological role in brain development, affecting dendritic elongation and branching of Purkinje cells, synaptogenesis, proliferation and migration of granule cells, and myelination
Furthermore, maternal thyroid failure even in terms of hypothyroxinemia alone (reduced FT4 and normal TSH levels), or subclinical hypothyroidism may be harmful to the human foetus. In fact, several rodent models demonstrated that maternal hypothyroidism may have different effects in the offspring: (i ) severe defects in the cerebral and cerebellar cortex, and in visual and auditory development
Maternal hypothyroxinemia is 150-200 times more prevalent than congenital hypothyroidism and results in lack of TH in embryo-foetal primordia during early pregnancy, before the onset of FTF [26, 27] . Severe iodine deficiency during pregnancy may induce maternal and foetal hypothyroxinemia, and cause neurological dysfunctions in the progeny [28] [29] [30] [31] [32] . Importantly, permanent alterations in the cytoarchitecture of the cerebral cortex appear in the progeny of hypothyroxinemic but not in hypothyroid dams [33] . [25, 34] ; (ii ) TRs are expressed in the cerebral cortex of first trimester human foetuses [15, 35] , as well as in rodent embryonic and adult neural tissues [36] [37] [38] .
The hypothesis that maternal THs can interact with embryonic TRs is supported by two facts: (i ) maternal T4, which is essential for the development of the brain and other foetal organs was found in coelomic and amniotic fluid in human beings and other species before FTF became active
However, direct evidence to support a physiological interaction between maternal TH and embryonic TRs during the early and late stages of embryogenesis is still lacking [25] .
To 
Materials and methods
Engineering the transgenic vector TRE2ϫ
To generate TRE2ϫ we used a truncated enhancer region of the native myelin basic protein (MBP-TRE-33) gene promoter [39] [40] [41] . We chose this sequence and configuration because it provides a selective and robust response to TRs (TR␤1ϾϾTR␣1) [39] . TRE2ϫ containing two MBP-TRE-18 [39, 40] Shih et al. [44] .
Hypothyroidism
Hypothyroidism was induced in TRE2ϫ transgenic female mice according to Schneider et al. [45] [46] . TSH was measured in 50 l serum using a sensitive, heterologous disequilibrium double-antibody precipitation RIA [46] . The 
Treatment with T3
We treated 14 
Results
␤-gal expression as a marker of TH action
) (P Ͻ 0.01) (Fig. 1B). The empty vector TK (without TRE sequences) was used as a negative control and did not elicit any LacZ transcriptional activity (data not shown).
Transgene expression in euthyroid transient embryos derived from TRE2؋ microinjection (transient model)
Maternal TH action during early stages of development in euthyroid transient transgenic embryos
At E9.5 no ␤-gal staining was detected (Fig. 3A) . TRs IHC at E9.5 showed weak expression of TR␣1, TR␤1 and TR␤2 in the midbrain and medulla oblongata (Fig. 3B-D (Fig. 4) (Fig. 6 ). TRs immunoreactivity was also evident in ␤-gal -areas (i.e. in the telencephalon). (Fig. 6) . RXRs expression was unmodified at E17.5 compared to the early stages examined, whereas RAR-␣ expression was strongly increased (Fig. 6 ).
RXR-␤ (Fig. 6) and RXR-␥ (data not shown) immunoreactivities were very weak, whereas RAR-␣ expression was intense
␤-gal expression in euthyroid embryos generated from a transgenic line (stable model) (Fig. 8A-C occipital bone primordium, the vertebrae and in the small intestine primordia (Fig. 8D-L (Fig. 10A) . Importantly, treatment with T3 in the hypothyroid mice rescued ␤-gal expression in the diencephalon primordium of E12.5 transgenic embryos (Fig. 10B) , producing a similar pattern to that observed in the euthyroid transgenic mouse embryos. [25] . However, recent evidence shows that maternal T4 is necessary for early physiological neurogenesis [33, 50] . Fig. 1A, B) [54] . The lack of TRE2ϫ transactivation before E11.5 may be related to different expression levels of TH transporters or type 2 and 3 deiodinases (D2 and D3) in the placenta during development [55] [56] [57] [58] [59] . Importantly, the main specific TH transporter, MCT8, has been recently identified by Friesema et al. [60] , and found to be expressed in human normal placenta at 6 weeks of gestation, with evidence for increasing expression during advanced gestation [55] . In addition, human placenta expresses high levels of D3 that appears to be important in maintaining circulating and tissue levels of foetal THs exceedingly low relative to maternal or adult levels. This mechanism has led to the concept that TH levels during development are tightly regulated within narrow limits to avoid either an excess or a deficiency of TH and that the D3, along with the D2, is widely responsible for this specific regulation [58] . Furthermore, Chan et al. have been reported that D2 and D3 mRNA levels and enzyme activities in human placenta were higher at early gestation than at late gestation [59] . Koopdonk-Kool et al. [61] [64, 65] . Less frequently, the expression levels of the transgene may be influenced by endogenous silencers or enhancers surrounding the regions of insertion [66] .
), and in the area of the future neurohypophysis, known as the infundibular recess of the third ventricle, indicated by the ectodermal primordium of the adenohypophysis (Rathke's pouch). At E13.5 ␤-gal expression was marked in the medulla oblongata, rostral extremity of the endolymphatic duct, origin of choroid plexus differentiating from roof of fourth ventricle, choroid plexus © 2009 The Authors Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 5 Double labelling with ␤-gal and nuclear receptors IHC at E11.5 and E12.5 of euthyroid transient transgenic embryos. (A-G): IHC against thyroid (TRs) and retinoid (RXRs) receptors in midsagittal sections of ␤-gal ϩ E11.5: (A) anti-TR␣1; (B) anti-TR␤1 (diencephalon, medulla oblongata); (C) anti-TR␤2 (diencephalon, medulla oblongata); (D) anti-TR␤1 (diencephalon, mesencephalic vesicle); (E) anti-RXR-␤ (diencephalon); (F) anti-TR␤2, detail in the area of the diencephalic vesicle; (G) anti-TR␣1, detail of the medulla oblongata and cranial spinal cord. Scale bar ϭ 1 mm in (A-E), 100 m in (F) and 400 m in (G). Arrows point to areas of colocalization between ␤-gal positivity and TRimmunoreactivity (diencephalon, medulla oblongata and spinal cord), whereas arrowheads point to areas of TRs-immunoreactivity devoid of ␤-gal staining (pons and dorsal root ganglia). (H-N): IHC with antibodies against TRs and RXRs in coronal sections of the brains of ␤-gal ϩ at E12.5: (H) anti-TR␣1; (J) anti-TR␤1; (K) anti-TR␤2; (I) anti-RXR-␤; (L) anti-RXR-␥; (M) anti-TR␤2, detail in the area of the developing hypothalamus; (N) anti-RXR-␤, detail of the cranial spinal cord (as in Fig. 4D). Scale bar ϭ 1 mm in (H-L) and 100 m in (M, N). 1: third ventricle; 2: fourth ventricle; 3: lateral ventricle. Thin arrow points to the colocalization of ␤-gal and TRimmunoreactivity in the diencephalon (thalamus), the arrowhead in the diencephalon (hypothalamus) and the thick arrow in the midbrain. within central part of lumen of fourth ventricle and the area above the olfactory epithelium. At stages E11.5, E12.5 and E13.5, similar to our findings in the transient transgenic embryos, we detected TRs and ␤-gal colocalization in the aforementioned anatomical primordia.
TH action during late stages of development in euthyroid stable transgenic embryos
At late stages of development diencephalic differentiation is almost complete and various anatomical sites can be distinguished. The © 2009 The Authors Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 6 Double labelling with ␤-gal and nuclear receptors IHC at a late stage (E17.5) of development of euthyroid transient transgenic embryos. (A-C) IHC with antibodies against thyroid (TRs) and retinoic (RARs) receptors: TR␣1 in (A), TR␤1 in (B), RAR-␣ in (C) and ␤-gal expression (D-F) in transgenic embryos at E17.5. Scale bar corresponds to 800 m in (A-C), 80 m in (D) and 200 m in (E-F). In (A-C) the arrows point to the developing cerebral cortex and the arrowheads to the spinal cord, respectively. In (D), ␤-gal expression in the developing small intestine, and in (E), ␤-gal expression (and in (F), TR␤2 immunostaining) in the nerves (arrows) innervating the whiskerpad (E, tangential section and F, transverse section). Higher magnification of TR␣1 (G), TR␤1 (H), RAR-␣ (I), and retinoid receptor RXR-␤ (J)
In summary, our results show that in euthyroid condition, maternal THs are able to cross placental barrier and to be transcriptionally active through embryonic TRs as early as E11.5 (early stage) of embryo-foetal development (Fig. 11). On the contrary, transplacental transfer of maternal THs is inhibited with maternal hypothyroidism (low T4 and T3 and high TSH) (Fig. 11). Treatment with T3 in hypothyroid pregnant mice (from approximately 4-6 weeks before pregnancy until E12.5) was able to switch on the TRE2ϫ transactivation and ␤-gal expression at the early stages (E12.5) of development when FTF is still not active.
Discussion
The simultaneous presence of maternal THs and nuclear thyroid receptors (TRs) during embryo-foetal development does not necessarily indicate that maternal THs are biologically active
Early CNS differentiation comprised two phases: (i ) neurulation and segmentation (E8-E9.5-E10.5) consisting of the formation of the three primary brain vesicles and (ii ) regionalization of the neural tube (i.e. diencephalon primordium, E11.5-E12.5)
Our [19, 25, 67, 68] . Of relevance, in the rat, changes in maternal TH availability during early stages of developmentequivalent to the end of the first and beginning of the second trimester in human beings -irreversibly affect neurogenesis and radial migration of neurons into the developing cerebral cortex and hippocampus [19] .
To [78] [79] .
Other transgenic mouse models were used to study TH action during embryo-foetal development. Quignodon [103] . These results supported the idea that repression by the unliganded TR␣1, and not the lack of TH, is responsible for the hypothyroid phenotype; THs therefore have a permissive effect on cerebellar granule cell migration through derepression by the TR␣1 isoform [103] . In addition, TR␣2 is unable to bind T3 and has been shown to exert dominant inhibitory action on T3/TRs-dependent transactivation of target genes [104] [105] [106] 
